DelveInsight’s Diffuse Cutaneous Systemic Sclerosis Market Insightsreport includes a comprehensive understanding of current treatment practices, emerging diffuse cutaneous systemic sclerosis drugs, ...

"Diffuse Cutaneous Systemic Sclerosis Pipeline"As per DelveInsight's assessment, globally, Diffuse Cutaneous Systemic Sclerosis pipeline constitutes 15+ key companies continuously working towards ...

Please provide your email address to receive an email when new articles are posted on . Patients showed no difference in skin fibrosis whether they were given low-dose oral glucocorticoids or not. One ...

Daval International today announced positive results from its Double-Blind Placebo-Controlled Phase II Clinical Study evaluating the safety and tolerability of AIMSPRO given as a monotherapy to ...

Daoussis D, Liossis SC, Tsamandas AC et al. (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 49: 271–80 Daoussis D, Liossis SC, Tsamandas ...

Each year 29 June marks World Scleroderma Day. This article highlights the symptoms, latest research and a genuine ‘diary’ experience from a US patient. The date 29 June was chosen to raise awareness ...

A 57-YEAR old British-Iranian woman was told by a skincare specialist that she had a "disease that turns you into stone". When Asal Shirazi was 39 she was told she had four to six months to live after ...

Rebecca Willers who runs the Shepreth Wildlife Park in Cambridgeshire was diagnosed in September with Diffuse Systemic Sclerosis - Representational Image AVM A 37-year-old British zoo owner is slowly ...

New York, USA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Diffuse Cutaneous Systemic Sclerosis Market Forecast: Opportunities and Growth Trends Upto 2034 | DelveInsight The diffuse cutaneous systemic sclerosis ...

Bosello SL, De Luca G, Rucco M et al. (2015) Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Seminars in Arthritis and Rheumatism 44: 428–36 ...

(MENAFN- GlobeNewsWire - Nasdaq) The diffuse cutaneous systemic sclerosis market landscape is evolving from conventional symptom-focused strategies toward therapies that specifically target fibrosis ...